Navigation Links
The PICA Group Will Become Part of ProAssurance
Date:10/28/2008

BIRMINGHAM, Ala. and NASHVILLE, Tenn., Oct. 28 /PRNewswire-FirstCall/ -- ProAssurance Corporation (NYSE: PRA) announced today that the PICA Group will become part of ProAssurance through an all cash, sponsored demutualization.

The PICA Group (PICA) is the nation's leading provider of professional liability to doctors of podiatric medicine, insuring approximately 9,800 podiatric physicians in 47 states and the District of Columbia. PICA insures other healthcare professionals and provides E&O insurance for a small, but growing, number of independent insurance agents through its PACO subsidiary. PICA wrote $99 million in premium in 2007, has $284 million in total assets and has maintained an A.M. Best rating of "A-" (Excellent) for the past 13 years.

"Bringing PICA into ProAssurance provides a compelling opportunity to grow our business, expand the number of states in which we operate, and broaden our pool of risk," said Stan Starnes, the Chief Executive Officer of ProAssurance. He added, "We are bringing together two companies that are recognized leaders in their respective markets. It adds to ProAssurance's legacy of intelligent growth through selective business combinations that has allowed ProAssurance to create a company offering unquestioned security for policyholders and steadily increasing value for shareholders."

Jerry D. Brant, DPM, the Chief Executive Officer of PICA, is equally enthusiastic about the proposed combination. He said, "We have found the ideal partner in ProAssurance -- we've known their management team for years and we know they are committed to treating every stakeholder fairly. This underscores the dedication to claims defense, underwriting excellence and meaningful risk management that have mad
'/>"/>

SOURCE ProAssurance Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008
2. AMD Global Telemedicine, Inc. Forms Telemedicine Design Group
3. Hanger Orthopedic Group, Inc. Exceeds Estimates on a 10% Sales Increase and a 28% EPS Increase to $0.23 for the Third Quarter 2008
4. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
5. Cadient Group Named to the Philadelphia 100(R) as One of the Regions Fastest-Growing Privately-Held Companies
6. More Hospitals Adopting Leapfrog Groups Never Events Policy Which Inculdes Apologies, Reporting, and Waiving Costs
7. AMERIGROUP Corporation Earns $0.74 Per Diluted Share
8. Wayport Signs Agreement with Sun Healthcare Group to Enable Public Internet Access : Sun's Inpatient Services Subsidiaries to Utilize Public Applications Managed by Wayport
9. Integrated Beverage Group Launches Childrens Throat Cooler(R)
10. Stronger Together: The Mohawk Group Supports Breast Cancer Awareness with T-Shirts Designed by Todd Oldham, Proceeds to Benefit Susan G. Komen
11. Environmental Tectonics Corporations Sterilization Systems Group Announces the Receipt of Three New Contracts
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Treatment Programs Benefit Depressed Workers 2Health News:Treatment Programs Benefit Depressed Workers 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 2Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 3Health News:AstraZeneca Recognized as One of Working Mother's '100 Best Companies' for the Sixth Consecutive Year 4Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 2Health News:Grand Opening of Regence Boys & Girls Club Marks a Milestone in Historic New Columbia Community Revitalization 3Health News:AHF Launches 'Public Health Division' 2Health News:AHF Launches 'Public Health Division' 3Health News:AHF Launches 'Public Health Division' 4Health News:'Making the Case:' special double issue of Critical Inquiry 2Health News:'Making the Case:' special double issue of Critical Inquiry 3Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 2Health News:Blue Cross of California and the California Governor's Council on Physical Fitness and Sports Launch 'Live Like a Champion Tour' 3
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 656 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 156 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 256 Year Old Grandmother Announces Attempt to Become First Woman to Complete the 4 Deserts 28TM 29 in Under a Year 56088 3Pelosi and Reid Invite President Obama to Address Congress 56085 1Chindex International Announces September Investor Conferences Participation 56083 1Chindex International Announces September Investor Conferences Participation 56083 2